CTCs
Angle, BioView Partner to Develop Quantitative HER2 Assay Using Circulating Tumor Cells
The companies said recent developments in HER2-targeted therapies have created new commercial opportunities for a blood-based test.
The firm cited new study results confirming that an assay analyzing circulating tumor cells isolated by its Parsortix platform can discriminate malignant pelvic masses.
4D Lifetec Raises $1.9M in Series B Financing to Support Lung Cancer Detection Test Launch
The company is hoping to accelerate its activities in Europe and is preparing to bring the cell-based test to the US by the end of next year.
Plus Therapeutics, Biocept Ink Lab Services Agreement for ReSPECT-LM Trial
Biocept will test patients with its CNSide cerebrospinal fluid cell capture assay to evaluate responses to Plus' radiotherapy drug candidate.
BioMark Diagnostics, Icahn Mount Sinai to Develop Multiomic Lung Cancer Tests
The partners also aim to develop a test for determining lung cancer subtype and stage using circulating tumor cells and metabolomics.